Recommendations on eligibility to PRIME scheme - Adopted at the CHMP meeting of 24-27 March 2025
Recommendations on eligibility to PRIME scheme - Adopted at the CHMP meeting of 24-27 March 2025
Recommendations on eligibility to PRIME scheme - Adopted at the CHMP meeting of 24-27 March 2025
Dear Colleagues,
On behalf of the EFIM Working Group on Diabetes and Obesity, we kindly invite you to help us disseminate a brief survey among your members. The goal is to assess how obesity education is integrated into internal medicine (IM) residency programs across Europe.
The survey is anonymous and takes less than 10 minutes to complete. It is aimed at individuals familiar with IM residency training curricula.
The insights gathered will help us:
Minutes of the PRAC meeting 28-31 October 2024
Minutes of the PRAC meeting 25-28 November 2024
Minutes of the PRAC meeting 2-5 September 2024
Minutes of the PRAC meeting 13-16 May 2024
Human medicines European public assessment report (EPAR): Quinsair, levofloxacin, Date of authorisation: 25/03/2015, Revision: 17, Status: Authorised
Human medicines European public assessment report (EPAR): Rasagiline ratiopharm, rasagiline, Date of authorisation: 12/01/2015, Revision: 10, Status: Authorised
Orphan designation: imetelstat sodium Treatment of myelodysplastic syndromes, 27/07/2020 Positive
ICH Guideline M13B on bioequivalence for immediate release solid oral dosage forms - additional strengths - Step 2b